Avacta Group Plc (AVCTF) Discusses Initial Faridoxorubicin Phase Ib Data and Safety Profile in Salivary Gland Cancer Transcript

SA Transcripts157.4K FollowersFollow5ShareSaveCommentsPlay Earnings CallPlay Earnings Call Avacta Group Plc (AVCTF) Discusses Initial Faridoxorubicin Phase Ib Data and Safety Profile in Salivary Gland Cancer December 17, 2025 5:00 AM EST Company Participants Paul FryChristina Coughlin - CEO & Executive DirectorDavid LiebowitzRuairidh Edwards Presentation Paul Fry Good morning, and welcome to the Avacta Group Plc investor presentation. [Operator Instructions] Before we begin, we'd like to submit the following poll. I'd now like to hand you over to Christina Coughlin, CEO. Good morning. Christina CoughlinCEO & Executive Director Thanks, Paul. Good morning, and thank you, everyone, for joining us for the data release for faridoxorubicin in Phase Ib in patients with salivary gland cancers. I'm joined today by 2 team members, our Chief Medical Officer, David Liebowitz; and our translational scientist for this program, Rory Edwards. Let's dive right in. pre|CISION is a FAP-activated drug delivery program, which essentially renders a given toxic drug for oncology silent in the bloodstream and active in the tumor by the binding of the pre|CISION peptide to mask the toxic payload in the bloodstream and in the normal tissues. Drug release is then only triggered at the tumor site by FAP, fibroblast activation protein, a protein that's been found in tumor supporting cells. The pre|CISION peptide masks the drug -- the toxic effects of the drug in normal tissues and in the bloodstream, and that drug is then released actively in the tumor by virtue of fibroblast activation protein or FAP, cleaving the peptide and releasing the active drug. Because normal tissues and the bone marrow essentially are not exposed to the toxic effects to the degree that they would be with conventional drugs. This has enabled prolonged treatment beyond that permitted with conventional therapy, which then translates into enhanced survival. We're excited to bring you the enhanced survival that we have seen with